Drug News
-
Meta Herbal Issues Voluntary Nationwide Recall of Magnum XXL 9800 Capsules Due to Presence of Undeclared Sildenafil
Meta Herbal is voluntarily recalling 500 blister packs of Magnum XXL 9800 2000 mg per capsule, to the consumer level.…
Read More » -
The US FDA Is Evaluating Plastic Syringes Made in China for Potential Device Failures
The U.S. Food and Drug Administration (FDA) is informing consumers, healthcare providers, and health care facilities that the FDA is…
Read More » -
Too Sick to Work? Expert Weighs the Decision
You’re sniffling, sneezing, and your nose is running like a faucet. It’s about that time of year when people everywhere…
Read More » -
Metastatic HER2-Positive Breast Cancer Market to Grow by 2032 at a 5.2% CAGR
DelveInsight’s recent Market Insights report on Metastatic HER2-Positive Breast Cancer provides a comprehensive analysis of current treatment practices, emerging drugs,…
Read More » -
Pharmaceutical Contract Research and Manufacturing Market size is set to grow by USD 121.35 billion from 2022-2027
According to a recent report by Technavio, the Pharmaceutical Contract Research and Manufacturing Market is poised to witness significant growth,…
Read More » -
Astellas’ Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
Astellas Pharma Inc. (TSE: 4503) is set to present 24-week results from the Phase 3b DAYLIGHT clinical trial at the…
Read More » -
FDA Investigating Serious Risk of T-cell Malignancy, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
AUDIENCE: Patient, Health Professional, Risk Manager, Oncology, Pharmacy ISSUE: The FDA has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive…
Read More » -
PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target
PRISM BioLab, Co. Ltd. (“PRISM”), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI)…
Read More » -
FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan)
AUDIENCE: Patient, Health Professional, Neurology, Dermatology, Allergy and Immunology, Pharmacy ISSUE: The FDA is warning that the antiseizure medicines, Keppra,…
Read More » -
Unomedical A/S Recalls VariSoft Infusion Sets Due to Damage to the Connector Piece Causing Unexpected Disconnections
The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices…
Read More »